Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by Accountprinceon Mar 06, 2023 10:58am
564 Views
Post# 35321285

Update on Dialco Deal with Infomed?

Update on Dialco Deal with Infomed?Eazeetrade1 - Jan 16 2023 - "Response from Spectral wrt to Dialco" below:

As such, Spectral was not required to file a material change report in respect of the Dialco Restructuring, nor was Spectral required to file or publicly disclose the transaction agreements relating to the Dialco Restructuring (the “Transaction Agreements”) on SEDAR.  As such, given that Spectral is not required by law to provide additional disclosure regarding the Dialco Restructuring, the provisions of the Transaction Agreements prevent further disclosure of the confidential terms of the Transaction Agreements without the approval of Infomed, which is not forth coming.  However, some further details of the Dialco Restructuring will be contained in our annual financial statements and accompanying MD&A for the period ended December 31, 2022, which we expect to publish at the end of March 2023.

If what was said to Eazeetrade1 was true we should know the "not material" secrets soon surrounding the loss of equity in Dialco to Infomed.  They "will be contained" in the annual documents.
<< Previous
Bullboard Posts
Next >>